Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review

Radiation Oncology Radiation Oncology UNIVERSITY OF TORONTO Henry Lam¹, Carlo DeAngelis¹, Edward Chow¹ Henry Lam¹, Carlo DeAngelis¹, Edward Chow¹ Health Sciences Centre

¹Sunnybrook Odette Cancer Centre, Toronto, Canada ²Mount Vernon Hospital, Imperial College, London, United Kingdom

Objective

- Determine pain response across multiple fraction radiation therapy (MFRT)
 - dacaa

Methods

- A literature search was conducted in Ovid MEDLINE(R) <1946 to July Week 3 2016>, Embase Classic & Embase <1947 to 2016 Week 30> and Cochrane Central Register of Controlled Trials <June 2016>
- Articles were included if they reported pain response of MFRT conventional external beam radiotherapy in the setting of a randomized controlled trial
- When possible, reported pain response was categorized into partial (PR), complete (CR) and overall



response (OR), and recorded separately as "Intent to Treat" (ITT) and "Evaluable Patients" (EP)

Results

PRISMA Flow Diagram

3719 articles identified from database Dose Response Rate search EP ITT 11 additional articles identified **Overall Response** 20Gy/2 13/27 (48%) 13/27 (48%) 3343 records after duplicates (n=387) 20Gy/5 270/448 (60%) 270/404 (67%) removed 20Gy/10 21/27 (78%) 21/27 (78%) 22.5Gy/5 126/157 (80%) 126/137 (92%) 24Gy/6 386/621 (62%) 386/561 (69%) 30Gy/10 435/851 (51%) 435/583 (75%) 3343 Title and Abstracts screened 3275 records excluded 30Gy/15 22/29 (76%) 22/29 (76%) Complete Response 20Gy/5 102/428 (24%) 102/379 (27%) 20Gy/10 10/27 (37%) 10/27 (37%) 68 full-text articles assessed for 44 full-text articles excluded, with 22.5Gy/5 62/167 (37%) 62/147 (42%) eligibility reasons 24Gy/6 175/578 (30%) 175/528 (33%) 30Gy/10 122/860 (14%) 122/580 (21%) 30Gy/15 12/29 (41%) 12/29 (41%) 7 full-text studies excluded, with 24 studies identified for potential Partial Response quantitative synthesis reasons 153/381 (40%) 20Gy/5 153/428 (36%) 20Gy/10 11/27 (41%) 11/27 (41%) 22.5Gy/5 64/147 (44%) 64/167 (38%) 17 papers included in quantitative 24Gy/6 186/578 (32%) 186/528 (36%) synthesis (meta-analysis) 30Gy/10 315/563 (56%) 315/831 (38%) 30Gy/15 10/29 (34%) 10/29 (34%) Study **CR and PR Criteria** Dose Time to Pain Pain Response Rates Pain OR CR PR Response Assessment

Pain Response by Dose

			, nespense ,							
		ΤοοΙ			ITT	EP	ITT	EP	ITT	EP
Amouzegar-	30Gy/10	4-point	1 month	CR: pain reduction of 2 grades or more	20/34	20/31	11/34	11/31	9/34	9/31
Hashemia et al 2008		numerical scale		PR: pain reduction of 1 grade or more but less than 2 grades	(59%)	(65%)	(33%)	(35%)	(26%)	(29%)
Anter 2015	20Gy/5	Numeric Rating	3 months	CR: no pain 3 months after RT	33/49	33/44	10/49	10/44	23/49	23/44
		Scale		PR: at least 2 points lower than baseline	(65%)	(75%)	(20%)	(23%)	(47%)	(52%)
Badzio et al	20Gy/5	4-point pain	4 weeks	CR: complete disappearance of pain and withdrawal of	52/74	52/62	24/74	24/62	28/74	28/62
2003		intensity scale		analgesic drugs PR: decrease in pain score or decrease in dose of analgesic drug	(70%)	(84%)	(32%)	(39%)	(39%)	(45%)
Bayard et al	30Gy/10	Visual Analog	1 month	CR: no pain	39/45	39/45	8/45	8/45	31/45	31/45
2014		Score		PR: decrease in pain score	(87%)	(87%)	(18%)	(18%)	(69%)	(69%)
Cole 1989	24Gy/6	Physician consult and patient diary	6 months	N/A	11/13 (85%)	11/11 (100%)	N/A	N/A	N/A	N/A
Foro Arnalot	30Gy/10	Ordinal pain	3 weeks	CR: absence of pain without need for increasing	71/82	71/82	11/82	11/82	60/82	60/82
et al 2008		scale		analgesia PR: improvement of equal or greater than 2 on scale with no need for increasing analgesia	(87%)	(87%)	(13%)	(13%)	(73%)	(73%)
Gaze et al	22.5Gy/5	Five-point	1 month	CR: complete pain relief	99/131	99/111	47/131	47/111	52/131	52/111
1997		categorical scale		PR: decrease in pain score	(76%)	(89%)	(36%)	(42%)	(40%)	(47%)
Hartsell et al	30Gy/10	Brief Pain	3 months	CR: no pain	188/443	188/285	51/443	51/285	137/443	137/285
2005		Inventory		PR: at least 2 points lower than initial response	(42%)	(66%)	(12%)	(18%)	(31%)	(48%)
Madsen 1983	24Gy/6	Visual Analog	4 weeks	N/A	14/30	14/30	N/A	N/A	N/A	N/A
		Scale			(47%)	(47%)				
	20Gy/2				13/27 (48%)	13/27 (48%)	N/A	N/A	N/A	N/A
Majumder et	30Gy/10	Visual Analog	1 month	CR: no pain	24/33	24/26	2/33	2/26	22/33	22/26
al 2012		Scale		PR: reduction of 2 or more points without analgesic increase	(73%)	(92%)	(6%)	(8%)	(67%)	(85%)
Nielson et al	20Gy/5	Visual Analog	4 weeks	CR: absence of pain	53/119	53/101	25/119	25/101	28/119	28/101
1998		Scale		PR: improvement of at least one-category	(45%)	(52%)	(21%)	(25%)	(24%)	(28%)
Niewald et al	30Gy/10	N/A	End of RT	N/A	38/46	38/46	10/46	10/46	28/46	28/46
1996					(83%)	(83%)	(22%)	(22%)	(61%)	(61%)
	20Gy/5				34/51	34/51	7/51	7/51	27/51	27/51
					(67%)	(67%)	(14%)	(14%)	(53%)	(53%)
Okawa et al	30Gy/15	5-point	N/A	CR: no pain	22/29	22/29	12/29	12/29	10/29	10/29
1988		categorical pain		PR: improvement in pain	(76%)	(76%)	(41%)	(41%)	(34%)	(34%)
	22.5Gy/5	scale			27/36	27/36	15/36	15/36	12/36	12/36
					(75%)	(75%)	(42%)	(42%)	(33%)	(33%)
	20Gy/10				21/27	21/27	10/27	10/27	11/27	11/27
					(78%)	(78%)	(37%)	(37%)	(41%)	(41%)
Price et al	30Gy/10	4-point pain	28 days	CR: complete loss of pain	41/148	41/48	13/148	13/48	28/148	28/48
1986		scale		PR: reduced pain	(28%)	(85%)	(9%)	(27%)	(19%)	(58%)
Roos et al	20Gy/5	4-point	4 weeks	CR: no pain with no analgesia or adjuvant analgesia	83/135	83/121	36/135	36/121	47/135	47/121
2005		categorical pain scale		PR: improvement in pain score by at least one grade with no increase in analgesia	(61%)	(69%)	(27%)	(30%)	(35%)	(39%)
Safwat et al 2007	20Gy/5	5-point	6 weeks	N/A	15/20	15/20	N/A	N/A	N/A	N/A
		_categorical scale			(75%)	(75%)			N 1 / A	
	30Gy/10				14/20	14/20	N/A	N/A	N/A	N/A
					(70%)	(70%)	/ /_	·		
Steenland et	24Gy/6	11-point scale	N/A	CR: 0 to 1 pain score, independent of analgesics	361/578	361/520	175/578	175/528	186/578	
ai 1999				Consumption PR: decrease in initial pains score by at least two points	(62%)	(69%)	(30%)	(33%)	(32%)	(35%)

Conclusions

- 22.5Gy/5 had the highest OR, 30Gy/15 had the better CR and 20Gy/2 had the best PR; their sample sizes are much smaller than some other dosages (which may account for the different response rates)
- Given the small differences seen, it is reasonable to conclude that no major difference exists between the schedules

We thank the generous support of Bratty Family Fund, Michael and Karyn Goldstein Cancer Research Fund, Joey and Mary Furfari Cancer Research Fund, Pulenzas Cancer Research Fund, Joseph and Silvana Melara Cancer Research Fund, and Ofelia Cancer Research Fund.